Related Experiment Videos
[On the treatment of arteriosclerotic retinopathy with Cosaldon A+E (author's transl)]
Insights
Cosaldon A+E improved visual function in patients with circulatory disorders and glaucoma. This treatment demonstrated positive effects on eye-ground vascular issues and chronic glaucoma symptoms.
Area of Science:
- Ophthalmology
- Vascular Medicine
Context:
- Investigated the efficacy of Cosaldon A+E in patients with severe vascular degenerative retinochoroidal circulatory disorders and chronic glaucoma.
- Addressed conditions with often unfavorable prognoses and limited treatment options.
Purpose:
- To evaluate the therapeutic effect of Cosaldon A+E on visual function in patients with ocular vascular and glaucomatous conditions.
- To assess the tolerability and impact on associated cerebrovascular insufficiency symptoms.
Summary:
- Cosaldon A+E was administered to 61 patients, with a majority experiencing severe retinochoroidal circulatory issues or chronic glaucoma.
- A significant improvement in visual function was observed in 43 patients, with moderate improvement in 8. Ten patients showed no change.
- Positive effects were noted in chronic glaucoma, including cases without elevated intraocular pressure, and on symptoms of chronic cerebrovascular insufficiency.
Impact:
- Cosaldon A+E offers a promising therapeutic approach for vascular eye-ground diseases like chorioretinopathy.
- The study suggests a beneficial role for Cosaldon A+E in managing chronic glaucoma and improving visual outcomes.
Abstract:
Cosaldon A+E was applied in 61 patients, most of whom presented severe vascular degenerative retinochoroidal circulatory disorders and chronic glaucoma. The treatment, mostly consisting of 3--2 x 1 tablet per day, was well tolerated and resulted in marked (43 patients) and moderate (8 patients) improvement of visual function. In ten patients the symptoms remained unchanged. Particularly the improvement found in 4 patients presenting chronic glaucoma "without pressure" are worth mentioning. Besides, the symptomatology of chronic cerebrovascular insufficiency presented by most of the patients was positively influenced. Cosaldon A+E above all renders more promising the treatment of vascular processes in the eye-ground, such as the chorioretinopathy, which, in view of the unfavourable prognosis of the disease, is deemed a remarkable progress. Likewise the product seems to exert a beneficial effect in patients with chronic glaucoma.